中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Ketamine for Pain in the Emergency Department

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态主动,不招募
赞助商
Hackensack Meridian Health

关键词

抽象

This study will prospectively compare the mean Numerical Rating Scale (NRS) pain score reduction amongst three recommended dosing strategies of intravenous ketamine (0.1 mg/kg, 0.2 mg/kg, and 0.3mg/kg) for acute pain in the emergency department (ED).This study will also examine the frequency of adverse events secondary to ketamine including fatigue, dizziness, nausea, headache, feeling of unreality, changes in hearing or vision, mood changes, generalized discomfort, and hallucinations, changes in vital signs. Subgroups for exploratory analysis based on the need for rescue analgesia within two hours of ketamine administration, adequate pain relief, previous opioid tolerance, and age (adults < 65 years old and > 65 years old).

描述

A literature review was performed that searched for randomized clinical trials involving ketamine IV boluses for acute pain in the Emergency Department. Studies involving continuous infusions or intranasal routes of ketamine administration were not included. Thirteen randomized clinical trials were identified meeting this criteria. None of these trials directly compared ketamine doses within the 0.1-0.3 mg/kg range for pain score reduction and adverse events. Many of these trials concluded with the recommendation that further studies were needed to evaluate the optimal dosing of ketamine for acute pain and determine which populations are most ideal for its use. This study will be the first to evaluate ketamine for acute pain in the emergency department at standard of care doses (0.1 mg/kg, 0.2 mg/kg, and 0.3 mg/kg IV) to determine which dose correlates with the most efficacy and safety.

This study will include the following procedures:

- Patient consent, screening, and enrollment will be performed by the treating resident or attending who will remain blinded

- Patient will be assigned a subject number

- Treating resident or attending will notify the ED pharmacist that a patient has been enrolled in the trial

- ED pharmacist will notify the IV room and place the study drug order

- Either the ED pharmacist or a pharmacy supervisor will randomize the subject based on the predetermined randomization list

- Study drug will be prepared as 0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg IV dose in a 100 mL solution of dextrose 5% or sodium chloride 0.9%

- ED pharmacist will promptly deliver the study drug to the ED

- Baseline vital signs will be assessed prior to starting the study drug infusion

- Study drug will be administered via IV infusion over 20 minutes

- Treating resident or attending will reassess the patient at 15 minutes from the end of infusion, at 30 minutes from the end of infusion, and then every 30 minutes for up to 120 minutes or until discharge, whichever is sooner

日期

最后验证: 02/29/2020
首次提交: 03/27/2019
提交的预估入学人数: 03/27/2019
首次发布: 03/28/2019
上次提交的更新: 03/08/2020
最近更新发布: 03/09/2020
实际学习开始日期: 05/02/2019
预计主要完成日期: 11/30/2020
预计完成日期: 11/30/2021

状况或疾病

Acute Pain

干预/治疗

Drug: Ketamine Injectable Product

相 4

手臂组

干预/治疗
Active Comparator: Arm 1: 0.1 mg/kg ketamine
0.1 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
Active Comparator: Arm 1: 0.2 mg/kg ketamine
0.2 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
Active Comparator: Arm 1: 0.3 mg/kg ketamine
0.3 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.

资格标准

有资格学习的年龄 21 Years 至 21 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

- Acute pain (including acute on chronic pain)

- Pain score of moderate to severe (> 4/10) on the Numerical Rating Scale

- Provider determines the patient requires intravenous ketamine for analgesia

Exclusion Criteria:

- History of hypersensitivity to ketamine

- Altered mental status

- Psychiatric illness

- Known history of renal or hepatic insufficiency

- Acute head or eye injury

- Suspected intracranial hypertension or mass

- Headache as the chief complaint

- Alcohol or drug abuse

- Received an analgesic within the last four hours

- History of congestive heart failure

- History of aortic or brain aneurysm

- Active Chest Pain

- Porphyria

- Active methadone treatment

- Pregnant or breastfeeding

- Signs of respiratory, hemodynamic, or neurologic compromise

- Systolic blood pressure < 90 mmHg or > 180 mmHg

- Heart rate < 50 beats per minute or > 150 beats per minute

- Respiratory rate < 10 breaths per minute or > 30 breaths per minute

- Glasgow Coma Score < 15

- Previously received ketamine < 0.3 mg/kg IV for acute pain in the emergency department

结果

主要结果指标

1. Pain score [2 hours post infusion completion]

Pain score using Numerical Rating Scale (NRS) post ketamine infusion. The Numerical Rating Scale (NRS) ranges from 0-to-10 with 0 being no pain and lower numbers representing less pain, so in this case lower numbers will represent better outcomes.

次要成果指标

1. Adverse Events [2 hours post infusion completion]

Frequency of adverse events secondary to ketamine including fatigue, dizziness, nausea, headache, feeling of unreality, changes in hearing or vision, mood changes, generalized discomfort, and hallucinations, changes in vital signs.

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge